Reinreude Back Pain Therapy Patch
NDC Package 85248-159-01
Package Information
Reinreude Back Pain Therapy (camphor 80mg menthol 24mg capsicum extract 16mg back pain therapy) patches is adults and children over 12 years. This formulation utilizes a patch delivery system. Marketed by Jiangxi Yudexi Pharmaceutical Co., Ltd, this product is identified by NDC 85248-159 and is authorized under FDA application M017.
Identification & Billing
Clinical Specifications
- Allergens - [CS]
- Cell-mediated Immunity - [PE] (Physiologic Effect)
- Dietary Proteins - [CS]
- Increased Histamine Release - [PE] (Physiologic Effect)
- Non-Standardized Food Allergenic Extract - [EPC] (Established Pharmacologic Class)
- Non-Standardized Plant Allergenic Extract - [EPC] (Established Pharmacologic Class)
- Plant Proteins - [CS]
- Vegetable Proteins - [CS]
Regulatory & Marketing
Hierarchy Structure
- 85248 - Jiangxi Yudexi Pharmaceutical Co., Ltd
- 85248-159 - Reinreude Back Pain Therapy
- 85248-159-01 - 10 PATCH in 1 BOX
- 85248-159 - Reinreude Back Pain Therapy
The NDC Directory contains ONLY information on final marketed drugs submitted to FDA electronically by labelers. A labeler might be a manufacturer, re-packager or re-labeler. The product information included in the NDC directory does not indicate that FDA has verified the information provided by the product labeler. Assigned NDC numbers are not in any way an indication of FDA approval of the product.
* Please review the full disclaimer at the bottom of this page.
Frequently Asked Questions
What is the distribution configuration for this product package?
The code 85248-159-01 identifies a specific commercial package of 10 patch in 1 box of Reinreude Back Pain Therapy, a human over the counter drug labeled by Jiangxi Yudexi Pharmaceutical Co., Ltd. This patch is formulated for topical use and contains camphoric acid; capsicum; menthol as the active substance.
Is this product currently listed with the FDA?
Yes, this product is active and verified within the NDC Directory. It was introduced to the market by Jiangxi Yudexi Pharmaceutical Co., Ltd on March 10, 2026. The current certification is valid through December 31, 2027.
How is this Jiangxi Yudexi Pharmaceutical Co., Ltd product billed for insurance claims?
For medical billing and reimbursement, this package follows the 11-digit CMS format: 85248015901. The table below illustrates the segment conversion from the 10-digit labeler code to the 11-digit provider format.
11-Digit Code Conversion
Billing payers usually require a 5-4-2 segment configuration. Below is the conversion from the 10-digit package format to the 11-digit billing format:
Note: The zero is added to the Product segment to maintain the 5-4-2 structure.